MedDataX Logo

The Effect of Terlipressin on Intesitnal Function in Septic Shock Patients

NCT ID: NCT02306239

Last Updated: 2014-12-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Terlipressin becomes a vasopressin for septic shock. But some studies found it may lead to severe intesitnal complications such as intestinal ischemia. The investigators study was designed to find the effect of terlipressin on intestinal function in septic shock patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Terlipressin Septic Shock

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

norepinephrine

patients received norepinephrine

Group Type ACTIVE_COMPARATOR

Norepinephrine

Intervention Type DRUG

terlipressin

patients received terlipressin

Group Type EXPERIMENTAL

Terlipressin

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Terlipressin

Intervention Type DRUG

Norepinephrine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* septic shock

Exclusion Criteria

* shock due to other reasons
* diagnosited intesitinal ischemia
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Liu ZiMeng

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Liu ZiMeng

surgical intensive care unit

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

liu zimeng, master

Role: PRINCIPAL_INVESTIGATOR

the first affiliated hospital of SUMS

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

the First Affiliated Hospital of Sumyetsan University

Guangzhou, Guangdong, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

liu zimeng, master

Role: CONTACT

Phone: 020-87755766

Email: [email protected]

zhang xuyu, master

Role: CONTACT

Phone: 020-87755766

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

liu zimeng, doctor

Role: primary

zhang xuyu, doctor

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2012A080204018

Identifier Type: -

Identifier Source: org_study_id